The $1 billion genome now costs about $100. Who got the money?
What has the collapse in the cost of reading DNA changed, and who has profited?
Reading a human genome cost $500 million to $1 billion the first time, by the US genome institute's estimate, and about $525 by 2022 on its production-cost data; companies now advertise $60 to $200 for the sequencing itself. Over the same years sequencing became routine in pregnancy screening, rare-disease diagnosis, cancer care and outbreak tracking, and a tool for choosing drug targets. The biggest machine maker didn't grow with it: Illumina's revenue was about flat from 2021 to 2025, while some testing companies grew more than tenfold and others went bankrupt.
- First genome
- $500M–$1B
- Cost by 2022 (NHGRI)
- $525
- Advertised now
- $60–$200
- Illumina revenue, 2025
- $4.34B
In five California children’s hospitals, doctors faced critically ill newborns whose illness they couldn’t explain. Instead of ordering one test after another, they sequenced the babies’ genomes from a blood sample. In the program, called Project Baby Bear, the results came back in about three days, found a diagnosis for 40% of 184 infants and changed the care of nearly a third (Rady Children’s).
A generation ago, that would have been science fiction. The first human genome took a decade and an international project to read. What changed most is the price of reading DNA. Over the same years its uses spread from hospitals into pregnancy care, cancer treatment, drug laboratories and outbreak tracking, and related genetic tools reached police work and the dairy barn. That has left investors a puzzle: the biggest machine maker hasn’t grown with the uses.
From a billion dollars to a restaurant bill
The US National Human Genome Research Institute (NHGRI) estimates that generating the first human genome sequence cost “at least $500 million” and possibly “as high as $1 billion.” By its own measure of what its funded centers spent per genome, the cost fell to about $95 million in 2001, $10,500 in 2011, $1,245 in late 2015 and $525 in May 2022, its last published point (NHGRI). Today, sequencer makers advertise $60 to $200 for the chemicals to read a human genome, and about $345 for long-read sequencing, each with its own conditions.
How fast the cost of sequencing a genome fell: average yearly decline (%)
The cost fell 63.5% a year from 2008 to 2015, as new machines arrived, then 12.3% a year from 2015 to 2022.
Since 2015Earlier periods
Show the data table
| Period | Average yearly decline (%) |
|---|---|
| 2001 to 2007 (older method) | 34.7 |
| 2008 to 2015 (next-generation machines) | 63.5 |
| 2015 to 2022 | 12.3 |
That fall outpaced the famous doubling of computer chips. But the institute’s numbers and the companies’ prices measure different things: the institute counts labor, machines and initial data processing, while the advertised prices cover chemicals. Both point the same way: producing the raw data got far cheaper. Clinical use still depends on the rest of the work, on evidence that a test helps patients and on who pays for it.
Where sequencing quietly went
These examples show how widely sequencing is now used; they don’t isolate how much lower prices alone made possible.
Pregnancy
Since 2011, expectant mothers have been able to screen for chromosome conditions with a blood draw that sequences fragments of fetal DNA, replacing some invasive tests. US obstetricians have advised offering such screening to all pregnant patients, regardless of age, since 2020. One company alone, Natera, processed about 3.5 million tests in 2025 across prenatal, carrier and cancer testing. In US fertility clinics, about 59% of analyzed IVF cycles in 2022 included screening embryos for abnormal chromosome numbers (Griffin et al.), though the American Society for Reproductive Medicine says its value as routine screening for all patients hasn’t been shown.
Rare disease
Families of children with undiagnosed conditions often spend years going from specialist to specialist; Genomics England puts the average at about five years. In a 2018 review of studies of children with suspected genetic disease, sequencing the whole genome found a diagnosis in 41% of cases, against 10% for the older chromosome test (Clark et al.). Programs in New York and England are now sequencing newborns: New York’s GUARDIAN study reported 110 confirmed findings among its first 4,000 babies that standard newborn screening hadn’t identified (JAMA), and England’s Generation Study had recruited more than 90,000 of a planned 100,000 by September.
Cancer
Doctors increasingly treat a tumor by its mutations rather than only by the organ it started in; US regulators approved the first such drugs in 2017 and 2018. Broad genetic profiling of common metastatic cancers rose from about 15% of privately insured US patients in 2020 to 24% in the first half of 2022, still a minority (JAMA Oncology). Blood tests that look for traces of tumor DNA after treatment have grown fast: Natera ran about 316,000 such tests in the third quarter of 2026 alone.
Drug development
Drug programs aimed at targets with human genetic evidence behind them have historically been about 2.6 times as likely to succeed, according to a 2024 study in Nature, though the advantage varied by disease area (Minikel et al.). That has turned DNA into raw material for drug discovery: the UK Biobank released about 490,000 whole genomes, linked to health records, in 2023, and Regeneron says it has sequenced more than 3 million people’s protein-coding DNA. The first approved CRISPR gene-editing therapy, for sickle-cell disease in 2023, edits a genetic control switch that genetic research had located, turning back on a form of hemoglobin the body normally stops making after birth.
Public health
Laboratories have shared 17.7 million coronavirus genomes through the GISAID database, and the Omicron variant was reported to the World Health Organization two days before WHO named it a variant of concern in November 2021 (GISAID). An international network of food-safety laboratories led by the FDA has sequenced more than 1.8 million bacteria samples to trace outbreaks; one study modelled US health benefits of nearly $500 million a year by 2019, against about $21 million a year of program cost (Brown et al.).
Daily life
Here the tool is often genotyping, a cheaper cousin that reads selected spots in the DNA. 23andMe had about 14 million customers in May 2025, after it filed for bankruptcy; its assets were sold for $305 million. DNA uploaded to genealogy databases has helped police identify suspects in decades-old cases, the Golden State Killer in 2018 among the best known. Even milk is different: after US dairy breeders began using genomic evaluations in 2009, the yearly genetic gain in Holstein bulls’ merit scores roughly doubled (CDCB).
How low can it go?
The official curve has flattened. On NHGRI’s data the cost fell 63.5% a year from 2008 to 2015 and 12.3% a year from 2015 to 2022, and the institute hasn’t published figures since; that history isn’t a forecast. Company announcements already advertised $100 to $200 genomes in 2022, and current claims run from $60 to $200, each on its own conditions, as machines from Ultima, Element, MGI and Roche compete with Illumina’s.
Some in the industry talk of a $10 genome. MGI’s chief scientific officer, Radoje Drmanac, says his team aims for it, and research groups are working on new sensors, but none of these is a priced, working product. In 2020, Stacey Gabriel, who leads the Broad Institute’s genomics platform, wrote that chemicals, flow cells and machines made up roughly 70% of the cost of sequencing a genome, and pointed to innovation, scale and competition as the routes to further falls.
The uses that need the most genomes, such as newborn programs, population studies and repeated cancer blood tests, are already being tried; the sources don’t say which would gain most from lower prices. And a lower price for the chemicals alone doesn’t remove these costs:
- Interpretation: a Toronto children’s hospital recorded about 200 minutes of analyst work and 90 minutes of a lab director’s time, on average, to interpret the genomes of one child and both parents. The US had 8,515 certified genetic counselors this year.
- Who pays: Medicare’s national coverage for this kind of sequencing is limited to cancer; there is no general national coverage of whole genomes (CMS).
- The whole workflow: a 2026 German study modelled sequencing a cancer patient’s tumor and normal genomes plus RNA at about €3,500 to €7,600 a case, depending on volume and assumptions (study).
- Privacy: The US law against genetic discrimination covers health insurance and jobs, but not life, disability or long-term-care insurance, and the sale of 23andMe’s data showed how much personal information a single company can hold.
Did the machine makers capture the gains?
Here is the investors’ puzzle. Two US-listed sequencer makers, Illumina and PacBio, together had $2.31 billion of revenue in 2015 and $4.50 billion in 2025, and Illumina’s revenue has been roughly flat since 2021, at $4.53 billion then and $4.34 billion last year. One analyst, Shawn Baker of the SanDiegOmics newsletter, estimates that all sequencer makers’ revenue has stayed around $5 billion a year for five years, an estimate whose yearly figures aren’t published. The companies cite several reasons for slower demand, from tighter research budgets to longer purchasing decisions. Price is part of the arithmetic too: if a supplier’s revenue per genome halves, customers must run twice as many genomes for its sales to stand still, though the filings don’t say how much of the flat revenue that explains.
Several companies that use sequencing to sell tests grew much faster over the same decade.
Revenue in 2025 as a multiple of 2015: sequencer makers and selected test makers
Revenue in 2025 was 2.0 times its 2015 level at Illumina and 1.7 times at PacBio, against 12.1 times at Natera and 82 times at Exact Sciences; Myriad's multiple was 1.1.
Sequencer makersTest makers
Show the data table
| Company | 2025 revenue ÷ 2015 revenue (x) |
|---|---|
| Exact Sciences | 82 |
| Natera | 12.1 |
| Veracyte | 10.4 |
| Illumina | 2.0 |
| PacBio | 1.7 |
| Myriad Genetics | 1.1 |
At the Nov 11 close, Natera’s stock market value, about $46 billion, was higher than Illumina’s, about $32 billion (our calculation from the latest reported share counts). Abbott agreed in November 2025 to buy Exact Sciences, maker of the Cologuard colon-cancer test, for about $21 billion in equity value, and completed the deal in March 2026.
That doesn’t settle who captured the value. These are revenues of selected, well-known companies, not profits or shareholder returns, and the test makers’ growth also came from insurance coverage, sales forces and acquisitions. The downstream business has its failures too: Invitae, a large genetic-testing lab, filed for bankruptcy in 2024 and sold its assets to Labcorp for $239 million, 23andMe went bankrupt in 2025, and Myriad Genetics’ revenue is about where it was in 2015. Some of the value went to drugmakers, to data and software companies, and to patients and health systems, as in the outbreak and intensive-care studies, in ways no stock price captures.
The makers themselves are in different positions. Illumina, still the largest, generates cash and buys back its shares; Oxford Nanopore is growing and targets breakeven on adjusted EBITDA in 2027; PacBio has opened a program to sell up to $100 million of new shares and owes $641 million of convertible notes. We look at PacBio’s cash in Can PacBio fund itself to breakeven?, and at Illumina’s strategy in our Illumina Long View.
| Company | Revenue | Gross margin | Cash and funding |
|---|---|---|---|
| Illumina (short reads) | $4.34B (2025); Q3 2026 $1.13B, +4.2% | 66.1% (2025) | $1.34B cash and short-term investments and $1.79B of term debt at Sep 27, 2026; $742M of buybacks in 2025 |
| Oxford Nanopore (long reads; London-listed) | £223.9M (2025); H1 2026 £116.7M, +10.5% | 62.2% (H1 2026) | £234.5M cash and liquid investments at Jun 30 |
| PacBio (long reads) | $160.0M (2025) | 36% non-GAAP (Q3 2026) | $199.4M cash and investments at Sep 30, 2026; $641M of convertible notes |
| Element Biosciences (private) | About $85M (2025, company estimate) | Not disclosed | Raised over $680M by 2024 |
| Ultima Genomics (private) | Not disclosed | Not disclosed | About $600M raised by 2022 |
Sources: Illumina 10-Q; Oxford Nanopore H1 2026; PacBio 10-Q; Element JPM 2026 presentation; Ultima 2022 funding. Gross margins are on different accounting bases and aren’t strictly comparable. Roche, Thermo Fisher and MGI don’t break out sequencing results comparably.
What comes next
The next decade’s question is less whether DNA can be read cheaply than who will pay to read it, and for what. Programs that sequence newborns and whole populations will test whether health systems will pay for routine genomes. US research budgets, a large source of academic sequencing, face a proposed cut. For investors, the open question is how much of the extra sequencing that cheaper genomes allow turns into revenue and profit, and for whom: the machine makers, the testing labs, the drugmakers or the data businesses. The record so far doesn’t answer it for the industry as a whole.
What to watch next
- Dec 11, 2026
- The stopgap that keeps US research funding (NIH) at its FY2026 level runs out; the FY2027 request is 10.8% lower on a comparable basis.
- Not dated
- Whether the genome institute publishes cost data after May 2022, and whether new machines priced at $60-$100 a genome ship in volume.
- Not dated
- Newborn-genome programs in New York (GUARDIAN) and England (the Generation Study): results, and whether health systems pay for routine use.
Quick questions
How much did the first human genome cost to sequence?
The US National Human Genome Research Institute puts the cost of generating the first human genome sequence at $500 million to $1 billion. The $2.7 billion often quoted was total US funding for the whole Human Genome Project.
How much does it cost to sequence a genome in 2026?
Companies advertise $60 to $200 for the sequencing chemicals for a human genome, and about $345 for long-read sequencing. The full cost is higher once sample preparation, analysis and, in medicine, interpretation are counted.
Who makes money from DNA sequencing?
The machine makers, led by Illumina, sell instruments and chemicals; Illumina's revenue was roughly flat from 2021 to 2025. Some testing companies that use sequencing, such as Natera, grew much faster, while others, including Invitae and 23andMe, went bankrupt.
+ 5 more
Accessed Nov 11, 2026: Shawn Baker (SanDiegOmics): the state of the DNA sequencing market, Jun 1, 2026
Accessed Nov 12, 2026: Clark et al., npj Genomic Medicine, 2018: diagnostic yield of genome sequencing in children (meta-analysis) · Rady Children's Institute: Project Baby Bear, rapid genome sequencing of critically ill infants · Minikel et al., Nature, 2024: genetic support and drug-development success · GISAID: SARS-CoV-2 data sharing by country (Sep 2026)
Quoting this? You may quote short excerpts under our reuse policy. Please credit WhyMyStockMoved.com and link to this page.